EMSAM (deprenyl patch): how a promising antidepressant was underutilized [Corrigendum]
Authors Asnis GM, Henderson MA
Published 4 November 2014 Volume 2014:10 Pages 2069—2070
Asnis GM, Henderson MA. Neuropsychiatr Dis Treat. 2014;10:1911–1923.
On page 1921 “[…] Dye and now Mylan Pharmaceutical took over the marketing of EMSAM from Bristol-Myers Squibb” should be “Dey and now Mylan Pharmaceutical took over the marketing of EMSAM from Bristol-Myers Squibb”.
On page 1921 “Both Dye and Mylan’s recent attempts at reanalysis […]” should be “Both Dey and Mylan’s recent attempts at reanalysis […]”.
On page 1921 “With over 14 years left in the patent of EMSAM, [...]” should be “with 4 years left in the patent of EMSAM, [...]”.
The authors apologize for these errors.
Read the original article
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF]